MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525945 | Name: Vatalanib free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vatalanib, also known as PTK787, is an orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms.

Chemical Structure

Vatalanib free base
Vatalanib free base
CAS#212141-54-3 (free base)

Theoretical Analysis

MedKoo Cat#: 525945

Name: Vatalanib free base

CAS#: 212141-54-3 (free base)

Chemical Formula: C20H15ClN4

Exact Mass: 346.0985

Molecular Weight: 346.82

Elemental Analysis: C, 69.26; H, 4.36; Cl, 10.22; N, 16.15

Price and Availability

Size Price Availability Quantity
50mg USD 500.00 2 weeks
100mg USD 800.00 2 weeks
250mg USD 1,500.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
212141-51-0 (HCl) 212141-54-3 (free base) 212142-18-2 (succinate)
Synonym
PTK787; PTK 787; PTK-787; ZK 222584; ZK222584; ZK-222584; CGP 79787; CGP-797870; ZK-232934; CGP79787D; PTK787/ZK 222584; CGP-7978
IUPAC/Chemical Name
N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
InChi Key
YCOYDOIWSSHVCK-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
SMILES Code
ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1
Appearance
White to off-white crystalline powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 346.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wu T, Song H, Wang R, Wang W, Xing J. A hyaluronic acid nanogels based exosome production factory for tumor photothermal therapy and angiogenesis inhibition. Int J Biol Macromol. 2024 Dec 30;293:139363. doi: 10.1016/j.ijbiomac.2024.139363. Epub ahead of print. PMID: 39743113. 2: Zaky MY, John J, Vashisht M, Singh P, Al-Hatamleh MAI, Siddoway K, Chen Z, Wang JH. Targeting Myeloid Cells in Head and Neck Squamous Cell Carcinoma: A Kinase Inhibitor Library Screening Approach. Int J Mol Sci. 2024 Nov 15;25(22):12277. doi: 10.3390/ijms252212277. PMID: 39596341; PMCID: PMC11595410. 3: Sarker A, Aziz MA, Hossen MB, Mollah MMH, Al-Amin, Mollah MNH. Discovery of key molecular signatures for diagnosis and therapies of glioblastoma by combining supervised and unsupervised learning approaches. Sci Rep. 2024 Nov 11;14(1):27545. doi: 10.1038/s41598-024-79391-2. PMID: 39528802; PMCID: PMC11554889. 4: Jin S, Paludetto MN, Kurkela M, Kahma H, Neuvonen M, Xiang X, Cai W, Backman JT. In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants. Eur J Pharm Sci. 2024 Dec 1;203:106884. doi: 10.1016/j.ejps.2024.106884. Epub 2024 Aug 30. PMID: 39218046. 5: Volf N, Vuerich R, Colliva A, Volpe MC, Marengon M, Zentilin L, Giacca M, Ring NAR, Vodret S, Braga L, Zacchigna S. Endothelial-to-mesenchymal transition enhances permissiveness to AAV vectors in cardiac endothelial cells. Mol Ther. 2024 Nov 6;32(11):3808-3814. doi: 10.1016/j.ymthe.2024.08.014. Epub 2024 Aug 22. PMID: 39175195; PMCID: PMC11573677. 6: Zhang H, Wang K, Chen F. Hyperipersions A-C, three new acylphloroglucinols from the branches and leaves of Hypericum perforatum L. with antiangiogenic activities. Nat Prod Res. 2024 Dec;38(23):4134-4140. doi: 10.1080/14786419.2023.2278176. Epub 2023 Dec 5. PMID: 38050718. 7: Zhou JB, Tang D, He L, Lin S, Lei JH, Sun H, Xu X, Deng CX. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation. Pharmacol Res. 2023 Aug;194:106830. doi: 10.1016/j.phrs.2023.106830. Epub 2023 Jun 19. PMID: 37343647. 8: Onda M, Ota A, Ito K, Ono T, Karnan S, Kato M, Kondo S, Furuhashi A, Hayashi T, Hosokawa Y, Kazaoka Y. Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma. Cancer Med. 2023 Aug;12(15):16416-16430. doi: 10.1002/cam4.6282. Epub 2023 Jun 21. PMID: 37341071; PMCID: PMC10469792. 9: Nakashima F, Giménez-Bastida JA, Luis PB, Presley SH, Boer RE, Chiusa M, Shibata T, Sulikowski GA, Pozzi A, Schneider C. The 5-lipoxygenase/cyclooxygenase-2 cross-over metabolite, hemiketal E2, enhances VEGFR2 activation and promotes angiogenesis. J Biol Chem. 2023 Apr;299(4):103050. doi: 10.1016/j.jbc.2023.103050. Epub 2023 Feb 21. PMID: 36813233; PMCID: PMC10040730. 10: Kojima A, Nadai M, Murayama N, Yamazaki H, Katoh M. Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2. Xenobiotica. 2022 Jul;52(7):669-675. doi: 10.1080/00498254.2022.2137068. Epub 2022 Oct 25. PMID: 36251932. 11: Mishra VS, Patil S, Reddy PC, Lochab B. Combinatorial delivery of CPI444 and vatalanib loaded on PEGylated graphene oxide as an effective nanoformulation to target glioblastoma multiforme: In vitro evaluation. Front Oncol. 2022 Aug 16;12:953098. doi: 10.3389/fonc.2022.953098. PMID: 36052261; PMCID: PMC9426685. 12: Xu H, Lafage-Proust MH, Bouazza L, Geraci S, Clezardin P, Roche B, Peyrin F, Langer M. Impact of Anti-Angiogenic Treatment on Bone Vascularization in a Murine Model of Breast Cancer Bone Metastasis Using Synchrotron Radiation Micro- CT. Cancers (Basel). 2022 Jul 15;14(14):3443. doi: 10.3390/cancers14143443. PMID: 35884504; PMCID: PMC9321934. 13: Ljoki A, Aslam T, Friis T, Ohm RG, Houen G. In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. Int J Mol Sci. 2022 Apr 12;23(8):4277. doi: 10.3390/ijms23084277. PMID: 35457095; PMCID: PMC9025250. 14: Goldwaser E, Laurent C, Lagarde N, Fabrega S, Nay L, Villoutreix BO, Jelsch C, Nicot AB, Loriot MA, Miteva MA. Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9. PLoS Comput Biol. 2022 Jan 26;18(1):e1009820. doi: 10.1371/journal.pcbi.1009820. PMID: 35081108; PMCID: PMC8820617. 15: Tullemans BME, Veninga A, Fernandez DI, Aarts MJB, Eble JA, van der Meijden PEJ, Heemskerk JWM, Kuijpers MJE. Multiparameter Evaluation of the Platelet- Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment. Int J Mol Sci. 2021 Oct 18;22(20):11199. doi: 10.3390/ijms222011199. PMID: 34681859; PMCID: PMC8540269. 16: Dong W, Han X, Bao C, Tai S, Bai Y, Xu L, Yang J, Leung T, Ao W, Dong W. Inhibitory Effects of Euphorbia ebracteolata Hayata Extract ECB on Melanoma-Induced Hyperplasia of Blood Vessels in Zebrafish Embryos. Evid Based Complement Alternat Med. 2021 Apr 26;2021:5543259. doi: 10.1155/2021/5543259. PMID: 33995546; PMCID: PMC8096565. 17: Kotini MP, Bachmann F, Spickermann J, McSheehy PM, Affolter M. Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos. Pharmaceuticals (Basel). 2020 Dec 30;14(1):25. doi: 10.3390/ph14010025. PMID: 33396726; PMCID: PMC7824571. 18: El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Arch Pharm (Weinheim). 2021 Mar;354(3):e2000219. doi: 10.1002/ardp.202000219. Epub 2020 Nov 16. PMID: 33197080. 19: Jeon SG, Lee HJ, Park H, Han KM, Hoe HS. The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice. Mol Brain. 2020 Sep 25;13(1):131. doi: 10.1186/s13041-020-00673-7. PMID: 32977842; PMCID: PMC7519542. 20: Mellor CL, Tollefsen KE, LaLone C, Cronin MTD, Firman JW. In Silico Identification of Chemicals Capable of Binding to the Ecdysone Receptor. Environ Toxicol Chem. 2020 Jul;39(7):1438-1450. doi: 10.1002/etc.4733. Epub 2020 Jun 4. PMID: 32335943; PMCID: PMC7781155.